High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients by Suspitsin, Evgeny N et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Hereditary Cancer in Clinical 
Practice
Open Access Research
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder 
mutations in Russian ovarian cancer patients
Evgeny N Suspitsin1,4, Nathalia Yu Sherina1, Daria N Ponomariova1, 
Anna P Sokolenko1,4, Aglaya G Iyevleva1,4, Tatyana V Gorodnova1, 
Olga A Zaitseva1, Olga S Yatsuk1, Alexandr V Togo1, Nathalia N Tkachenko6, 
Grigory A Shiyanov6, Oksana S Lobeiko2, Nadezhda Yu Krylova5, 
Dmitry E Matsko3, Sergey Ya Maximov2, Adel F Urmancheyeva2,5, 
Nathalia V Porhanova6 and Evgeny N Imyanitov*1,4,5
Address: 1Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, St. Petersburg, Russia, 2Department of Gynecology, N.N. Petrov 
Institute of Oncology, St. Petersburg, Russia, 3Laboratory of Tumor Morphology, N.N. Petrov Institute of Oncology, St. Petersburg, Russia, 
4Department of Genetics, St. Petersburg Pediatric Medical Academy; Department of Oncology, St. Petersburg, Russia, 5Department of Oncology, 
St. Petersburg Medical Academy of Postgraduate Studies, St. Petersburg, Russia and 6Department of Gynecology, Regional Oncological Hospital, 
Krasnodar, Russia
Email: Evgeny N Suspitsin - suspitsin@hotmail.com; Nathalia Yu Sherina - natalya.sherina@gmail.com; 
Daria N Ponomariova - rooibos86@rambler.ru; Anna P Sokolenko - annasokolenko@mail.ru; Aglaya G Iyevleva - aglayai@inbox.ru; 
Tatyana V Gorodnova - gorodnova00@mail.ru; Olga A Zaitseva - zayats_vorchun@mail.ru; Olga S Yatsuk - olga-yatsuk@mail.ru; 
Alexandr V Togo - a_togo@mail.ru; Nathalia N Tkachenko - gnbxrf2007@yandex.ru; Grigory A Shiyanov - grigoriysochi@yandex.ru; 
Oksana S Lobeiko - lobeiko-oksana@mail.ru; Nadezhda Yu Krylova - njur71@mail.ru; Dmitry E Matsko - d.matsko@mail.ru; 
Sergey Ya Maximov - s.maximov@mail.ru; Adel F Urmancheyeva - adaurm@mail.ru; Nathalia V Porhanova - reytingandrey@mail.ru; 
Evgeny N Imyanitov* - evgeny@imyanitov.spb.ru
* Corresponding author    
Abstract
Background: A significant portion of ovarian cancer (OC) cases is caused by germ-line mutations
in BRCA1 or BRCA2 genes. BRCA testing is cheap in populations with founder effect and therefore
recommended for all patients with OC diagnosis. Recurrent mutations constitute the vast majority
of BRCA defects in Russia, however their impact in OC morbidity has not been yet systematically
studied. Furthermore, Russian population is characterized by a relatively high frequency of CHEK2
and NBS1 (NBN) heterozygotes, but it remains unclear whether these two genes contribute to the
OC risk.
Methods: The study included 354 OC patients from 2 distinct, geographically remote regions (290
from North-Western Russia (St.-Petersburg) and 64 from the south of the country (Krasnodar)).
DNA samples were tested by allele-specific PCR for the presence of 8 founder mutations (BRCA1
5382insC, BRCA1 4153delA, BRCA1 185delAG, BRCA1 300T>G, BRCA2 6174delT, CHEK2
1100delC, CHEK2 IVS2+1G>A, NBS1 657del5). In addition, literature data on the occurrence of
BRCA1, BRCA2, CHEK2 and NBS1 mutations in non-selected ovarian cancer patients were
reviewed.
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Results: BRCA1 5382insC allele was detected in 28/290 (9.7%) OC cases from the North-West
and 11/64 (17.2%) OC patients from the South of Russia. In addition, 4 BRCA1 185delAG, 2
BRCA1 4153delA, 1 BRCA2 6174delT, 2 CHEK2 1100delC and 1 NBS1 657del5 mutation were
detected. 1 patient from Krasnodar was heterozygous for both BRCA1 5382insC and NBS1
657del5 variants.
Conclusion: Founder BRCA1 mutations, especially BRCA1 5382insC variant, are responsible for
substantial share of OC morbidity in Russia, therefore DNA testing has to be considered for every
OC patient of Russian origin. Taken together with literature data, this study does not support the
contribution of CHEK2 in OC risk, while the role of NBS1 heterozygosity may require further
clarification.
Background
Ovarian cancer (OC) is a major cause of oncological mor-
tality in females, with a life-time risk approaching to
approximately 1.7%. Poor outcome of OC is largely
attributed to the failure to diagnose the disease at early,
potentially curable stages; small tumors of the ovary are
usually asymptomatic and likely to be missed by routine
gynecological examination [1]. Genetic component may
play a key role in OC etiology: depending on the country
and ethnicity, 5–50% OC cases are attributed to the germ-
line heterozygous inactivation of BRCA1 or BRCA2 genes
(see additional file 1). Interestingly, while BRCA-related
breast carcinomas (BC) are usually strongly enriched by
early onset and familial cancer cases, this relationship is
less evident for OC. Although the majority of the studies
confirm some association between the presence of BRCA
mutation and younger patients age (for BRCA1 but not
BRCA2) or family history of the disease (see additional
file 1), the strength of this trend is not enough to limit
BRCA testing by particular categories of OC patients;
instead, the OC diagnosis itself is often considered as a
sufficient indication for BRCA analysis. Actually, the
occurrence of BRCA mutations in randomly recruited OC
cases is fairly similar to the estimates, which are obtained
in preselected high-risk categories of women with breast
cancer [2-41].
In Russia, a significant fraction of early-onset and/or bilat-
eral and/or familial BC cases is caused by founder muta-
tions in cancer genes [42]. Presence of the "founder effect"
significantly decreases the costs of the DNA testing, thus
relaxing the criteria for patients selection. While distribu-
tion of germ-line mutations in Russian breast cancer cases
has been studied with sufficient level of comprehension,
no systematic analysis has been undertaken yet for ovar-
ian cancer. Furthermore, breast cancer in Russia and some
neighboring countries is caused not only by mutations in
BRCA genes, but also by heterozygous inactivation of the
CHEK2 and NBS1 [42]. It remains unclear, whether the
latter 2 genes contribute to OC predisposition as well, or,
vice versa, their impact is limited by breast cancer risk.
Materials and methods
Ovarian cancer cases were collected in 2 geographically
distinct regions of Russian Federation. 290 patients (mean
age: 53 years; age range: 21–89 years) were recruited in the
N.N. Petrov Institute of Oncology (St.-Petersburg), which
provides the treatment to the residents of North-Western
Russia. In addition, the study included 64 women with
OC (mean age: 59 years; age range: 33–78 years) from the
regional oncological hospital of the city of Krasnodar,
which is located in Southern Russia, more than two thou-
sands kilometers aside from the first spot of patients col-
lection. Almost all patients had Slavic ethnic origin. DNA
isolation, design of PCR assays and other relevant techni-
cal information is described in detail in our earlier report
[42].
Results
The observed frequencies of founder mutations are pre-
sented in the Table 1. BRCA1 5382insC mutation was by
far the most prevalent, accounting for 28/290 (9.7%) OC
cases from the North-West and 11/64 (17.2%) from the
South of Russia. Jewish BRCA1 variant, BRCA1 185delAG,
was the second by prevalence: it was detected in 3/290
(1.0%) cases from St.-Petersburg and in 1/64 (1.6%)
patients from Krasnodar. BRCA1 4153delA mutation was
revealed only in 2/290 (0.7%) subjects from the first
cohort, and BRCA1 300T>G was not observed in any sam-
ple tested. When both patients groups were pooled
together, the occurrence of founder BRCA1 mutations
approached to 12.7% (45/354). Other breast cancer asso-
ciated founder mutations (BRCA2, CHEK2, NBS1) were
detected only in single patients. Interestingly, 1 OC
patient from Krasnodar carried both BRCA1 5382insC
and NBS1 657del5 mutation; tumor tissue from this
woman demonstrated loss of heterozygosity of the wild-
type NBS1 allele, but intact status of BRCA1 gene. This
unique case is presented in detail in a separate publication
[43]. Based on the results of DNA test and the history of
cancer diseases in her family, this patient opted for pro-
phylactic subcutaneous nipple-sparing mastectomy cou-
pled with the immediate breast reconstruction by siliconeHereditary Cancer in Clinical Practice 2009, 7:5 http://www.hccpjournal.com/content/7/1/5
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implant; morphological examination of the excised mam-
mary tissue revealed no evidence for the tumor growth.
Distribution of founder mutations in various OC sub-
groups is analyzed in Table 2. Patients from St.-Petersburg
did not demonstrate association with early age at onset,
while the mutation carriers were somewhat overrepre-
sented in younger patients from Krasnodar (10/34
(29.4%) in patients aged </= 60 years versus 2/30 (6.7%)
in older women; p = 0.02). Family history records were
available only for the patients from the North-West; no
association between the presence of the germ-line muta-
tions and reporting OC or BC in a first-degree relative has
been observed. Furthermore, there was no significant dif-
ference between carriers and non-carriers with respect to
other clinico-pathological parameters of the disease.
Discussion
This study was designed to analyze the impact of selected
founder mutations in OC morbidity in Russia. The panel
of genetic variants included several alleles, which are char-
acteristic for Slavic people and/or residents of Baltic
regions (BRCA1 5382insC, BRCA1 4153delA, BRCA1
300T>G, CHEK2 1100delC, CHEK2 IVS2+1G>A, NBS1
657del5), and/or European Jews (BRCA1 185delAG,
BRCA2 6174delT). This study confirmed the utmost role
of BRCA1 5382insC mutation in cancer morbidity:
indeed, this single genetic defect is responsible for as
many as 1 out of 9 ovarian cancers and 1 out of 25 breast
cancers occurring in Russia. Furthermore, BRCA1
5382insC demonstrates unique geographic spread, being
among the most prevalent BRCA variants in Poland,
Byelorussia, Baltic republics, various cities of Russian Fed-
eration (St.-Petersburg, Tomsk, and Krasnodar), and pos-
sibly some Mediterranean countries [42,44-49]. The
remarkable role of the founder effect contradicts to the
wide-spread view that the extreme complexity of the his-
tory of Russian Empire resulted in huge genetic diversity
of Russian residents. It is important to emphasize, that
recent investigations show surprisingly high level of
genetic homogeneity for the 3 analyzed Slavic-speaking
populations, i.e. Russians, Ukrainians and Poles [50].
These unexpected data are in good agreement with the
lack of language diversity within the Russian Federation:
astonishingly, people residing nearby Baltic sea or in the
Far East speak exactly the same dialect, despite being sep-
arated by the distance of 11000 kilometers.
Other BRCA1 founder mutations are relatively rare in Rus-
sian ovarian or breast cancer cases [42]. BRCA1 4153delA
allele was initially considered to be characteristic for
familial OC in Russia [44]; furthermore, it was suggested
that this variant confers specific predisposition to the
ovarian but not breast carcinogenesis [25,48]. Our data do
not confirm these statements. Jewish BRCA1 185delAG
allele is occasionally detected in Russian OC and BC cases,
while Baltic BRCA1 300T>G variant demonstrates null
occurrence and therefore has to be excluded from the local
diagnostic panel [42]. Taken together with other reports
on OC patients or healthy controls [36-38,51], this study
does not support the role of CHEK2 gene lesions in OC
predisposition (Table 1). On the other hand, the possibil-
ity of limited contribution of NBS1 germ-line mutations
in OC risk cannot be fully excluded. Previously, Plisiecka-
Table 1: Founder mutations in Russian ovarian cancer cases
St.-Petersburg (n = 290) Krasnodar (n = 64)
BRCA1 5382insC 28 (9.7%) 11 (17.2%)*
BRCA1 4153delA 2 (0.7%) -
BRCA1 185delAG 3 (1.0%) 1 (1.6%)
BRCA1 300T>G - -
BRCA2 6174delT 1 (0.3%) -
CHEK2 1100delC 2 (0.7%) -
CHEK2 IVS2+1G>A - -
NBS1 657del5 - 1 (1.6%)*
Total carriers 36 (12.4%) 12 (18.8%)*
*1 patient from Krasnodar carried both BRCA1 5382insC and NBS1 657del5 mutations.Hereditary Cancer in Clinical Practice 2009, 7:5 http://www.hccpjournal.com/content/7/1/5
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Table 2: Frequencies of founder mutations in distinct categories of ovarian cancer patients
Clinical variable St.-Petersburg (n = 290) Krasnodar (n = 64)
Age at onset (years)
< 41 2/36 (5.6%) 1/1 (100.0%)
41–60 22/172 (12.8%) 9/33 (27.2%)
> 60 12/82 (14.6%) 2/30 (6.7%)
Non-informative -
Family history*
Positive 1/9 (11.1%) -
Negative 33/266 (12.4%) -
Non-informative 2/15 (13.3%) 12/64 (18.8%)
T status
T1 2/52 (3.8%) 3/10 (30.0%)
T>1 32/220 (14.5%) 8/53 (15.1%)
Non-informative 2/18 (11.1%) 1/1 (100.0%)
N status
N0 12/109 (11.0%) 1/4 (25.0%)
N1 7/53 (13.2%) 1/1 (100.0%)
N2 1/1 (100.0%) -
Non-informative 16/127 (12.6%) 10/59 (16.9%)
M status
M0 22/186 (11.8%) 11/58 (19.0%)
M1 6/63 (9.5%) 0/4 (0.0%)
Non-informative 8/41 (19.5%) 1/2 (50.0%)
Tumor grade
1–2 7/96 (7.3%) 9/48 (18.8%)
3 23/154 (14.9%) 3/16 (18.8%)Hereditary Cancer in Clinical Practice 2009, 7:5 http://www.hccpjournal.com/content/7/1/5
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Hałasa et al. [39] identified 2 NBS1 657del5 mutation car-
riers among 117 OC patients. In the present study, the fre-
quency of NBS1 heterozygosity in OC patients (0.3%) did
not differ significantly from the estimate obtained in
healthy Russian women (0.6%) [52]. However, tumor tis-
sue from the BRCA1/NBS1 heterozygous carrier from our
OC group contained biallelic inactivation of NBS1 but
not BRCA1 [43].
Most of the published investigations reported a correla-
tion between the presence of BRCA1 mutation and family
history of breast/ovarian cancer as well as earlier onset of
the disease. Some reports also noticed association of
BRCA1 heterozygosity with non-mucinous tumor histol-
ogy, high tumor grade, and improved survival (see addi-
tional file 1). Nevertheless, almost all investigators agree
that neither lack of family history nor late disease onset
are reliable indicators of BRCA1 wild-type status in OC
patients, therefore DNA testing of non-selected ovarian
cancer cases is recommended by some laboratories. Our
study failed to detect relationships between BRCA1 germ-
line mutations and first-degree family history. There are
some factors, which could complicate the analysis of ped-
igrees for BC and OC cases. First of all, BRCA1-related can-
cers are mainly gender-specific: i.e. male carriers of BRCA1
defects do not experience significantly elevated cancer risk
due to absence of the main target organs (breasts and ova-
ries); therefore, family history negative BRCA1-associated
BC and OC are particularly likely in case of paternal trans-
mission of the mutation. Other confounding effects are
related to specific circumstances of recent history of Rus-
sian Federation. Huge human losses caused by historical
turbulences in the XX century, taken together with limited
average life expectancy, led to the situation when many
BRCA1 carriers simply failed to achieve the age of cancer
manifestation due to premature death. Another factor,
that may increase the number of false-negative pedigrees,
is a relatively low number of children per family in the
modern Russia; in other words, many of questioned
patients could recall only a small number if any of their
adult female relatives. Finally, an analysis of heredity is
frequently ignored by Russian medical professionals, i.e.
family history records in medical charts may simply lack a
sufficient level of accuracy.
Conclusion
This study indicates that all ovarian cancer patients of Rus-
sian ethnic origin have to be screened for the presence of
a few BRCA1 founder mutations (BRCA1 5382insC,
BRCA1 185delAG, BRCA1 4153delA). Introduction of
this cheap DNA test into routine medical practice may
help to identify yet healthy relatives of OC patients, who
carry the same genetic defect and thus will benefit from
tight surveillance and/or prophylactic surgery. Further-
more, recent findings suggest that BRCA1-associated ovar-
ian cancers may require distinct strategy for the disease
treatment [53].
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Non-informative 6/40 (15.0%) -
Tumor histology
Serous adenocarcinoma 36/250 (14.4%) 7/41 (17.1%)
Mucinous adenocarcinoma 0/9 (0.0%) 0/2 (0.0%)
Adenocarcinoma, not otherwise specified 0/16 (0.0%) 3/11 (27.3%)
Other 0/15 (0.0%) 2/10 (20.0%)
*Family history was defined as the presence of breast and/or ovarian cancer in mother or sister.
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